Support Line: 0800 002 9002
General Enquiries: 01223 870008

Results for "cabozantinib"

Cabozantinib

Cabozantinib

Cabozantinib is used to treat renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Cabozantinib is given in tablet form and is Available in all of UK. The combination therapy of Cabozantinib...

Belzutifan+cabozantinib shows promise for advanced RCC, study shows

Belzutifan+cabozantinib shows promise for advanced RCC, study shows

belzutifan+cabozantinib combination therapy show promise as an option for advanced kidney cancer patients already treated with immunotherapy, according to study. Immunotherapies, such as anti-PD-1 and anti-PD-L1, have become standard first line therapies for patients...

CheckMate data support 1st nivo–cabo in advanced RCC

CheckMate data support 1st nivo–cabo in advanced RCC

CheckMate 9ER HRQoL data support first-line nivolumab–cabozantinib in advanced RCC People receiving nivolumab plus cabozantinib for advanced renal cell carcinoma (RCC) report less decline in health-related quality of life (HRQoL) during treatment than those given...

Over 20 Years of KCUK

Over 20 Years of KCUK

For the over 20 years Kidney Cancer UK has been a consistent, prominent and influential name working to support patients through the approval of drugs for kidney cancer patients, better treatments and a clear treatment pathway.

Persist! Persist! Persist!

Persist! Persist! Persist!

A  special blog for Kidney Cancer Awareness Week 2023 by Richard Jetten I was 41 and running our own Spanish Tapas restaurant when one morning I noticed my wee had turned red, it looked just like Cherryade! Initially I dismissed this as a bad bottle of red wine from...

Cabo + nivo & ipi delays kidney cancer progression

Cabo + nivo & ipi delays kidney cancer progression

Adding cabozantinib (Cabometyx) to nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival (PFS) in patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma (RCC), according to the primary analysis of the...

Scott Kelly: Lessons learned

Scott Kelly: Lessons learned

Lessons learned Hello everyone, my name is Scott. I’m in my late 50s and have been living with Stage 4 kidney cancer (clear cell renal cell carcinoma – ccRCC) since 2019. Unfortunately, it took almost a year to...

The Road to A&E

The Road to A&E

A  special blog for Kidney Cancer Awareness Week 2023 by Janet. Having had a successful career as a chartered accountant and mathematics teacher, I was talked into travelling to Spain which meant selling the beautiful house we built in my father’s garden, leaving him...

Adding Cabometyx to Immunotherapy Improves Kidney Cancer Outcomes

Adding Cabometyx to Immunotherapy Improves Kidney Cancer Outcomes

The addition of Cabometyx to Opdivo and Yervoy improved outcomes for patients with advanced kidney cancer, according to recent research. Patients with advanced renal cell carcinoma (RCC; the most common type of kidney cancer) of intermediate or poor risk tended to...

Whack-A-Mole with kidney cancer

Whack-A-Mole with kidney cancer

A blog by Charlotte Connolly In January 2019 I asked my husband to leave. And my journey began! I was working as an Education Welfare Officer travelling around schools, which I had been doing for nearly 20-years, when one day out of the blue I began bleeding heavily...

Opdivo + Yervoy fails adjuvant phase 3 trial

Opdivo + Yervoy fails adjuvant phase 3 trial

Bristol-Myers Squibb has revealed that its checkpoint inhibitor combination of Opdivo and Yervoy failed a phase 3 trial as adjuvant (post-surgery) therapy for renal cell carcinoma (RCC), the most common form of kidney cancer writes pharmaphorum.com The disappointing...

Savolitinib not significantly efficacious in aRCC

Savolitinib not significantly efficacious in aRCC

Savolitinib, alone or in combination with durvalumab, did not demonstrate significant efficacy in patients with advanced clear cell renal cancer, according to a presentation at ASCO Annual Meeting. “We know drugs like cabozantinib have multiple activities, including...

Drug Treatments for Kidney Cancer

Glossary of Terms

There are many terms associated with kidney cancer. Kidney Cancer UK has collated a comprehensive glossary of terms to help patients, carers and health professionals find the information they need.

Support Line

OPEN 5 DAYS A WEEK

0800 002 9002

Kidney Cancer Information

Whether you are recently diagnosed, undergoing or completed treatment for kidney cancer, are a carer, a friend or family of a kidney cancer patient, Kidney Cancer UK is here for you .

For further support call our Support Line to talk to a member of our Health team on 0800 002 9002.